| CINF |
Report |
Non-GAAP Operating EPS (Q2'26) |
BEAT |
pred ~$1.95 vs. cons $1.82 |
MEDIUM |
| CINF |
Report |
P&C Combined Ratio (Q2'26) |
MISS |
pred ~95.5% vs. cons ~94.0% |
LOW |
| CINF |
Report |
Consolidated Net Written Premium Growth (Q2'26 YoY) |
MISS |
pred ~5.0% vs. cons ~6.5% |
MEDIUM |
| CINF |
Guide |
FY2026 Combined Ratio Target Commentary |
LOWER |
guide ~96% vs. cons ~95% (FY2026) |
LOW |
| CINF |
Guide |
Commercial Lines Renewal Pricing Trend |
LOWER |
guide ~2% vs. cons ~3% (Q3 2026) |
MEDIUM |
| CINF |
Guide |
Share Buyback Pace |
BETTER |
guide ~1.0M shares vs. cons ~0.8M shares (Q3 2026) |
LOW |
| CINF |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.2% |
— |
MEDIUM |
| CINF |
Return |
5-day cumulative residual |
-2.3% (FOLLOW-THROUGH) |
A likely cat-driven combined-ratio miss and further confirmation of commercial/personal/E&S pricing deceleration should push sell-side to trim FY2026 EPS and combined-ratio estimates even after an EPS beat, since the EPS beat is lower-quality (investment income/tax, not underwriting) while premium growth and margin trajectory both point to negative out-period revisions; with the stock having already re-rated to ~1.8x book on a hot run into the print, disappointment on growth/margin quality plus reiterated 92-98% target caution should extend the initial negative reaction over the following days rather than reverse it. |
LOW |